Evidence map›Paper›PMID 31176670›Full record

ArticleJournal of cystic fibrosis : official journal of the European Cystic Fibrosis Society2020

Abnormal pro-gly-pro pathway and airway neutrophilia in pediatric cystic fibrosis.

Andrew R Turnbull, Chloe J Pyle, Dhiren F Patel, Patricia L Jackson, Tom N Hilliard, Nicolas Regamey, Hui-Leng Tan, Sarah Brown, Rebecca Thursfield, Christopher Short and 8 more

Open access · hybridAbstract read
In one paragraph

Article in Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
1.9field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 21 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Mechanisms by which the cystic fibrosis transmembrane conductance regulator may influence SARS-CoV-2 infection and COVID-19 disease severity.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2023
    Article
  6. Article
  7. LC-MS/MS method for proline-glycine-proline and acetylated proline-glycine-proline in human plasma.Journal of chromatography. B, Analytical technologies in the biomedical and life sciences · 2023
    Article
  8. Article
  9. Article
  10. Metabolomics of airways disease in cystic fibrosis.Current opinion in pharmacology · 2022
    Review
  11. Proteases, Mucus, and Mucosal Immunity in Chronic Lung Disease.International journal of molecular sciences · 2021
    Review
  12. Review
  13. Review
  14. Targeting Proteases in Cystic Fibrosis Lung Disease. Paradigms, Progress, and Potential.American journal of respiratory and critical care medicine · 2020
    Review
  15. Review
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 6 institutions in 3 countries.

Andrew R TurnbullCystic Fibrosis and Chronic Lung Infection, National Heart & Lung Institute, Imperial College London, United Kingdom; Paediatric Respiratory Medicine, Royal Brompton & Harefield NHS Foundation Trust, London, United Kingdom.
Chloe J PyleInflammation Repair and Development, National Heart and Lung Institute, Imperial College London, London SW7 2AZ, United Kingdom.
Dhiren F PatelInflammation Repair and Development, National Heart and Lung Institute, Imperial College London, London SW7 2AZ, United Kingdom.
Patricia L JacksonDivision of Pulmonary, Allergy and Critical Care Medicine, Program in Protease and Matrix Biology, Gregory Fleming James Cystic Fibrosis Centre and Lung Health Center, University of Alabama at Birmingham, Birmingham, AL 35294, United States of America; Birmingham V.A. Medical Centre, Birmingham, AL 35294, United States of America.
Tom N HilliardCystic Fibrosis and Chronic Lung Infection, National Heart & Lung Institute, Imperial College London, United Kingdom; Paediatric Respiratory Medicine, Royal Brompton & Harefield NHS Foundation Trust, London, United Kingdom.
Nicolas RegameyPaediatric Respiratory Medicine, Children's Hospital, Lucerne, Switzerland.
Hui-Leng TanPaediatric Respiratory Medicine, Royal Brompton & Harefield NHS Foundation Trust, London, United Kingdom.
Sarah BrownPaediatric Respiratory Medicine, Royal Brompton & Harefield NHS Foundation Trust, London, United Kingdom; Inflammation Repair and Development, National Heart and Lung Institute, Imperial College London, London SW7 2AZ, United Kingdom.
Rebecca ThursfieldAlder Hey Children's NHS Foundation Trust, Liverpool L14 5AB, United Kingdom.
Christopher ShortCystic Fibrosis and Chronic Lung Infection, National Heart & Lung Institute, Imperial College London, United Kingdom.
Megan Mc FieInflammation Repair and Development, National Heart and Lung Institute, Imperial College London, London SW7 2AZ, United Kingdom.
Eric W F W AltonCystic Fibrosis and Chronic Lung Infection, National Heart & Lung Institute, Imperial College London, United Kingdom.
Amit GaggarDivision of Pulmonary, Allergy and Critical Care Medicine, Program in Protease and Matrix Biology, Gregory Fleming James Cystic Fibrosis Centre and Lung Health Center, University of Alabama at Birmingham, Birmingham, AL 35294, United States of America; Birmingham V.A. Medical Centre, Birmingham, AL 35294, United States of America.
J Edwin BlalockDivision of Pulmonary, Allergy and Critical Care Medicine, Program in Protease and Matrix Biology, Gregory Fleming James Cystic Fibrosis Centre and Lung Health Center, University of Alabama at Birmingham, Birmingham, AL 35294, United States of America.
Clare M LloydInflammation Repair and Development, National Heart and Lung Institute, Imperial College London, London SW7 2AZ, United Kingdom.
Andrew BushPaediatric Respiratory Medicine, Royal Brompton & Harefield NHS Foundation Trust, London, United Kingdom; Inflammation Repair and Development, National Heart and Lung Institute, Imperial College London, London SW7 2AZ, United Kingdom.
Jane C DaviesCystic Fibrosis and Chronic Lung Infection, National Heart & Lung Institute, Imperial College London, United Kingdom; Paediatric Respiratory Medicine, Royal Brompton & Harefield NHS Foundation Trust, London, United Kingdom.
Robert J SnelgroveInflammation Repair and Development, National Heart and Lung Institute, Imperial College London, London SW7 2AZ, United Kingdom. Electronic address: robert.snelgrove@imperial.ac.uk.
Imperial College London · GBRoyal Brompton & Harefield NHS Foundation Trust · GBUniversity of Alabama at Birmingham · USAlder Hey Children's NHS Foundation Trust · GBLung Institute · USUniversity of Teacher Education Lucerne · CH

Funding

A Novel Proteolytic System of Pulmonary InflammationR01HL102371 · NHLBI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI GAGGAR, AMIT · 2010 to 2021
$3.3M
HL-A New Pathway for Neutrophil-induced Airway InflammationR01HL077783 · NHLBI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI BLALOCK, J EDWIN · 2006 to 2016
$3.2M
Acquired LTA4H Dysfunction in COPDR01HL110950 · NHLBI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI BLALOCK, J EDWIN · 2012 to 2015
$2.0M
Genetics of Smoke-Altered LTA4H in COPDR01HL126596 · NHLBI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI BLALOCK, J EDWIN, CASTALDI, PETER · 2015 to 2018
$1.6M
PGP, A Possible Biomarker for COPD Exacerbations and or ProgressionR01HL114439 · NHLBI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI BLALOCK, J EDWIN · 2012 to 2015
$1.5M
Prolyl Endopeptidase-Mediated Matrix Remodeling and Inflammation in COPDI01BX001756 · VA · BIRMINGHAM VA MEDICAL CENTER · PI GAGGAR, AMIT · 2015 to 2018
–
BLRD VA I01 BX001756NHLBI NIH HHS R01 HL077783NHLBI NIH HHS R01 HL102371NHLBI NIH HHS R01 HL110950NHLBI NIH HHS R01 HL114439NHLBI NIH HHS R01 HL126596Wellcome TrustWellcome Trust 086718/Z/08/ZWellcome Trust 209458/Z/17/Z
6 · The paper itself

Abstract

backgroundProline-glycine-proline (PGP) is a bioactive fragment of collagen generated by the action of matrix metalloproteinase-9 (MMP-9) and prolylendopeptidase (PE), and capable of eliciting neutrophil chemotaxis and epithelial remodelling. PGP is normally then degraded by leukotriene A

methodsBroncho-alveolar lavage (BAL) fluid was obtained from 38 CF (9 newborns and 29 older children) and 24 non-CF children. BAL cell differentials and levels of PGP, MMP-9, PE and LTA

resultsWhilst PGP was present in all but one of the older CF children tested, it was absent in non-CF controls and the vast majority of CF newborns. BAL levels of MMP-9 and PE were elevated in older children with CF relative to CF newborns and non-CF controls, correlating with airway neutrophilia and supportive of PGP generation. Furthermore, despite extracellular LTA

conclusionsA striking imbalance between PGP-generating and -degrading enzymes enables PGP accumulation in CF children from early life and potentially supports airway neutrophilia.

Indexed as

Cystic FibrosisNeutrophilsAirway RemodelingBronchoalveolar Lavage FluidBronchoscopyChemotaxis, LeukocyteChildFemaleHumansInfant, NewbornInflammationLeukocyte ElastaseMaleMatrix Metalloproteinase 9OligopeptidesProlineLeukocyte ElastaseMatrix Metalloproteinase 9OligopeptidesProlineprolyl-glycyl-prolineProlyl OligopeptidasesCystic fibrosisMatrikineNeutrophilProtease

Identifiers

PMID31176670
PMCPMC7001103
OpenAlexW2948261226

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.